Almirall Sues Aleor to Block Copies of Aczone Acne Treatment

Sept. 24, 2021, 3:52 PM

Almirall said a generic version of Aczone Gel 7.5% proposed by Aleor Dermaceuticals, a joint venture between Alembic and closely held Orbicular Pharmaceutical, infringes a patent related to the treatment for acne vulgaris.

  • Almirall is seeking court order blocking copies until patent has expired and cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Newark, New Jersey
  • Patent covers composition of topical treatment and methods for using it, complaint says
  • A board of U.S. Patent and Trademark Office in May 2020 canceled patent after Amneal requested review of its validity ...

To read the full article log in. To learn more about a subscription click here.